The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sequential neoadjuvant chemotherpy with nab-paclitaxel plus gemcitabine and FOLFIRINOX in locally advanced pancreatic cancer (LAPC): A PILOT study.
Volker Kunzmann
No relevant relationships to disclose
Ingo Hartlapp
No relevant relationships to disclose
Michael Scheurlen
No relevant relationships to disclose
Hermann Einsele
No relevant relationships to disclose
Justus Mueller
No relevant relationships to disclose
Werner Kenn
No relevant relationships to disclose
Ulrich Steger
No relevant relationships to disclose
Christoph T. Germer
No relevant relationships to disclose